Bacil Pharma Ltd Stock Price Today (NSE: BACPHAR)
Fundamental Score
Bacil Pharma Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Bacil Pharma Ltd share price today is ₹21.10, up +3.74% on NSE/BSE as of 16 September 2026. Bacil Pharma Ltd (BACPHAR) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹30.28 (Cr). The 52-week high for BACPHAR share price is ₹61.80 and the 52-week low is ₹10.65. At a P/E ratio of 34.76x, BACPHAR is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 6.21% and a debt-to-equity ratio of 0.00.
Bacil Pharma Ltd Share Price Chart — NSE/BSE Historical Performance
Bacil Pharma Ltd share price chart: 10.01% return over the past month. 52-week high ₹61.80, 52-week low ₹10.65.
Bacil Pharma Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹21.35 | ₹21.35 | ₹19.33 | ₹21.10 | 1.23L (Cr) | |
| ₹20.34 | ₹20.34 | ₹20.00 | ₹20.34 | 1.40L (Cr) | |
| ₹19.24 | ₹19.38 | ₹18.83 | ₹19.38 | 72.70K (Cr) | |
| ₹18.00 | ₹18.58 | ₹16.82 | ₹18.46 | 1.60L (Cr) | |
| ₹17.70 | ₹17.70 | ₹17.00 | ₹17.70 | 19.74K (Cr) | |
| ₹16.86 | ₹16.86 | ₹16.80 | ₹16.86 | 25.51K (Cr) | |
| ₹16.06 | ₹16.06 | ₹15.10 | ₹16.06 | 64.45K (Cr) | |
| ₹15.25 | ₹15.30 | ₹14.65 | ₹15.30 | 20.09K (Cr) | |
| ₹14.17 | ₹14.58 | ₹14.17 | ₹14.58 | 49.67K (Cr) | |
| ₹13.30 | ₹13.89 | ₹13.00 | ₹13.89 | 66.05K (Cr) |
Bacil Pharma Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹13.23 | ₹21.35 | ₹12.25 | ₹21.10 | +59.49% | |
| ₹20.76 | ₹20.76 | ₹10.65 | ₹11.43 | -44.94% | |
| ₹39.80 | ₹41.84 | ₹21.85 | ₹21.85 | -45.10% | |
| ₹50.50 | ₹55.00 | ₹37.35 | ₹39.99 | -20.81% | |
| ₹54.12 | ₹59.90 | ₹49.00 | ₹50.03 | -7.56% | |
| ₹47.73 | ₹61.80 | ₹45.42 | ₹56.95 | +19.32% | |
| ₹47.38 | ₹51.90 | ₹43.71 | ₹47.73 | +0.74% | |
| ₹39.48 | ₹51.46 | ₹35.06 | ₹48.35 | +22.47% | |
| ₹37.42 | ₹46.90 | ₹36.12 | ₹39.70 | +6.09% | |
| ₹40.20 | ₹43.69 | ₹32.52 | ₹35.64 | -11.34% | |
| ₹32.83 | ₹42.00 | ₹26.69 | ₹40.09 | +22.11% | |
| ₹43.65 | ₹47.90 | ₹34.55 | ₹34.55 | -20.85% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Bacil Pharma Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Bacil Pharma Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of BACPHAR across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Excellent EPS Growth (53.06% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (77.46% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Healthy Liquidity Position (Current Ratio: 17.21)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Below-Average Return on Equity (6.21%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-0.98%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Profit Decline Concern (-102.99%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Negative Free Cash Flow (₹-3.05 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Low Promoter Commitment (0.00%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Bacil Pharma Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Bacil Pharma Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Bacil Pharma LtdBacil Pharma Lt...Selected✓ BACPHAR • 524516 | 31/100 | ₹21.10₹21 | ₹30.28₹30.28 | 34.76Average 34.8 Average | 6.21%Poor 6.21% Poor | -0.98%Poor -0.98% Poor | 0.00Excellent 0.0 Excellent | 77.46%Excellent 77.46% Excellent | — — | 0.00% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1864.90₹1865 | ₹447445.46₹447445.46 | 37.00Average 37.0 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9488.00₹9488 | ₹251432.00₹251432.00 | 86.09Average 86.1 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4930.00₹4930 | ₹166860.78₹166860.78 | 78.75Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1127.40₹1127 | ₹112514.52₹112514.52 | 25.13Average 25.1 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1363.10₹1363 | ₹110118.03₹110118.03 | 32.66Average 32.7 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1937.00₹1937 | ₹104646.43₹104646.43 | 95.61Average 95.6 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1698.90₹1699 | ₹97754.71₹97754.71 | 26.55Average 26.5 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.00₹2100 | ₹96022.50₹96022.50 | 17.35Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1145.00₹1145 | ₹95607.50₹95607.50 | 29.59Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2265.00₹2265 | ₹93544.50₹93544.50 | 45.77Average 45.8 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price447445.46 Cr
- Divi's Laboratories Limited share price251432.00 Cr
- Torrent Pharmaceuticals Limited share price166860.78 Cr
- Zydus Lifesciences Limited share price112514.52 Cr
- Cipla Limited share price110118.03 Cr
Bacil Pharma Ltd Quarterly Performance
Latest quarterly metrics for BACPHAR — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
N/A
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-102.99%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
77.46%
Compounded annual net profit growth over 5 years
Bacil Pharma Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for BACPHAR — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Bacil Pharma Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Bacil Pharma Ltd (BACPHAR) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Bacil Pharma Ltd
About BACPHAR (Bacil Pharma Ltd)
Bacil Pharma Ltd is a dynamic pharmaceutical company rooted in the bustling metropolis of Mumbai, India. Established in 1987, BACPHAR has steadily grown into a significant player i...n the Indian pharmaceutical landscape. With a keen focus on meeting the diverse healthcare needs of the nation, they are dedicated to providing high-quality, affordable medicines to improve the lives of people across the country. Driven by a commitment to scientific innovation and ethical business practices, the company operates with a strong sense of social responsibility, ensuring that its products are accessible to all segments of society. They are steadfast in their mission to contribute meaningfully to the healthcare ecosystem in India. BACPHAR's comprehensive product portfolio encompasses a wide range of therapeutic areas, catering to various medical conditions. From commonly prescribed tablets and convenient capsules to specialized injectables and soothing ointments, they offer a solution for many healthcare requirements. The company takes immense pride in adhering to stringent quality control measures at every stage of the production process, from sourcing the finest raw materials to employing cutting-edge manufacturing techniques. This commitment to excellence ensures that each medicine that bears the BACPHAR name is safe, effective, and of the highest possible standard. Their dedication to quality has earned them the trust and confidence of healthcare professionals and patients alike. Strategically headquartered in Mumbai, a hub of pharmaceutical activity, BACPHAR benefits from its proximity to key industry resources and talent. This advantageous location enables them to stay at the forefront of pharmaceutical advancements and maintain a competitive edge in the market. Their extensive distribution network spans across India, ensuring that their products reach even the most remote areas of the country. BACPHAR is committed to continuous improvement, constantly investing in research and development to expand its product offerings and adapt to the evolving needs of the healthcare industry. The company remains focused on sustainable growth and creating lasting value for its stakeholders.
Company Details
Key Leadership
BACPHAR Share Price: Frequently Asked Questions
What is the current share price of Bacil Pharma Ltd?
Bacil Pharma Ltd (BACPHAR) trades at ₹21.10 on NSE and BSE. Market cap ₹30.28 (Cr). Educational data only.
What is the P/E ratio of Bacil Pharma Ltd?
Bacil Pharma Ltd has a P/E of 34.76x vs industry average 34.89x.
What is the Bull Run score for Bacil Pharma Ltd?
Bacil Pharma Ltd has a Bull Run score of 31/100 based on 25+ financial parameters.
Does Bacil Pharma Ltd pay dividends?
Bacil Pharma Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Bacil Pharma Ltd?
Bacil Pharma Ltd has ROE of 6.21%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Bacil Pharma Ltd?
Bacil Pharma Ltd has debt-to-equity of 0.00.
Is Bacil Pharma Ltd a good investment?
Bull Run gives Bacil Pharma Ltd a score of 31/100. This is not investment advice — consult a SEBI-registered advisor.